Nelarabine Injection (larger vial)
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)
ApprovedActive
Key Facts
Indication
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL)
Phase
Approved
Status
Active
Company
About Shorla Oncology
Shorla Oncology is a private, commercial-stage biotech specializing in the re-innovation of oncology therapeutics for niche, high-need populations, particularly in women's and pediatric cancers. Its strategy involves optimizing formulations of existing drugs to improve accessibility, affordability, and clinical utility. The company has achieved its first FDA approval for a larger vial size of nelarabine and is advancing a broader pipeline, leveraging a team with deep experience in niche oncology drug development and commercialization.
View full company profile